Drug interactions involving the new second- and third-generation antiepileptic drugs

References

• Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Ther. Drug Monit.24(1), 91–103 (2002).
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Fröscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia43(4), 365–385 (2002).
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol.2(6), 347–356 (2003).
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol.2(8), 473–481 (2003).
   PubMed Web of Science ®Google Scholar
• Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br. J. Clin. Pharmacol.61(3), 246–255 (2006).
   PubMed Web of Science ®Google Scholar
• Rowan AJ, Meijer JWA, de Beer-Pawlikowski N et al. Valproate–ethosuximide combination therapy for refractory absence seizures. Arch. Neurol.40, 797–802 (1983).
   PubMedGoogle Scholar
• Pisani F, Oteri G, Russo MF, Di Perri R, Perucca E, Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia40(8), 1141–1146 (1999).
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res.26, 423–432 (1997).
   PubMed Web of Science ®Google Scholar
• Tsiropoulos I, Gichangi A, Andersen M, Bjerrum L, Gaist D, Hallas J. Trends in utilization of antiepileptic drugs in Denmark. Acta Neurol. Scand.113(6), 405–411 (2006); Erratum in: Acta Neurol. Scand.114(1), 70 (2006).
   PubMed Web of Science ®Google Scholar
• van de Vrie-Hoekstra NW, de Vries TW, van den Berg PB, Brouwer OF, de Jong-van den Berg LT. Antiepileptic drug utilization in children from 1997–2005 – a study from The Netherlands. Eur. J. Clin. Pharmacol.64(10), 1013–1020 (2008).
   PubMedGoogle Scholar
• Lackner TE, Cloyd JC, Thomas LW, Leppik IE. Antiepileptic drug use in nursing home residents: effect of age, gender, and comedication on patterns of use. Epilepsia39(10), 1083–1087 (1998).
   PubMedGoogle Scholar
• Crawford P, Lee P. Gender difference in management of epilepsy – what women are hearing. Seizure8(3), 135–139 (1999).
   PubMed Web of Science ®Google Scholar
• Pack AM, Davis AR, Kritzer J et al. Antiepileptic drugs: are women aware of interactions with oral contraceptives and potential teratogenicity? Epilepsy Behav.14(4), 640–644 (2009).
   PubMedGoogle Scholar
• Spina E, Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia43(Suppl. 2), 37–44 (2002).
   PubMed Web of Science ®Google Scholar
• Mula M. Anticonvulsants – antidepressants pharmacokinetic drug interactions: the role of CYP450 system in psychopharmacology. Curr. Drug Metab.9, 730–777 (2008).
   PubMed Web of Science ®Google Scholar
• Johannessen Landmark C, Larsson PG, Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders – a population-based study of prescriptions. Epilepsy Res.87(1), 31–39 (2009).
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res.83(1), 1–43 (2009).
   PubMed Web of Science ®Google Scholar
• McCormack PL, Robinson DM. Eslicarbazepine acetate. CNS Drugs23(1), 71–79 (2009).
   PubMed Web of Science ®Google Scholar
• Elger C, Halász P, Maia J et al. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group Phase III study. Epilepsia50(3), 454–463 (2009).
   PubMed Web of Science ®Google Scholar
• Almeida L, Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics4, 88–96 (2007).
   PubMed Web of Science ®Google Scholar
• O’Neil MG, Perdun CS, Wilson MB, McGown ST, Patel S. Felbamate-associated fatal acute hepatic necrosis. Neurology46(5), 1457–1459 (1996).
   PubMed Web of Science ®Google Scholar
• Palmer KJ, McTavish D. Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Drugs45(6), 1041–1065 (1993).
   PubMed Web of Science ®Google Scholar
• Thompson CD, Gulden PH, Macdonald TL. Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration. Chem. Res. Toxicol.10(4), 457–462 (1997).
   PubMed Web of Science ®Google Scholar
• Graves NM, Holmes GB, Fuerst RH, Leppik IE. Effect of felbamate on phenytoin and carbamazepine serum concentrations. Epilepsia30(2), 225–229 (1989).
   PubMed Web of Science ®Google Scholar
• Wagner ML, Graves NM, Leppik IE et al. The effect of felbamate on valproic acid disposition. Clin. Pharmacol. Ther.56(5), 494–502 (1994).
   PubMed Web of Science ®Google Scholar
• Reidenberg P, Glue P, Banfield CR et al. Effects of felbamate on the pharmacokinetics of phenobarbital. Clin. Pharmacol. Ther.58(3), 279–287 (1995).
   PubMed Web of Science ®Google Scholar
• Albani F, Theodore WH, Washington P et al. Effect of felbamate on plasma levels of carbamazepine and its metabolites. Epilepsia32(1), 130–132 (1991).
   PubMed Web of Science ®Google Scholar
• Contin M, Riva R, Albani F, Baruzzi AA. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. Ther. Drug Monit.21(6), 604–608 (1999).
   PubMedGoogle Scholar
• Wagner ML, Graves NM, Marienau K, Holmes GB, Remmel RP, Leppik IE. Discontinuation of phenytoin and carbamazepine in patients receiving felbamate. Epilepsia32(3), 398–406 (1991).
   PubMed Web of Science ®Google Scholar
• Hussein G, Troupin AS, Montouris G. Gabapentin interaction with felbamate. Neurology47(4), 1106 (1996).
   PubMed Web of Science ®Google Scholar
• Tisdel KA, Israel DS, Kolb KW. Warfarin-felbamate interaction. First report. Ann. Pharmacother.28, 805 (1994).
   PubMedGoogle Scholar
• Saano V, Glue P, Banfield CR et al. Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. Clin. Pharmacol. Ther.58(5), 523–531 (1995).
   PubMed Web of Science ®Google Scholar
• Rodrigues JP, Edwards DJ, Walters SE et al. Gabapentin can improve postural stability and quality of life in primary orthostatic tremor. Mov. Disord.20(7), 865–870 (2005).
   PubMedGoogle Scholar
• Lean MJ. Gabapentin. Epilepsia36(Suppl. 2), S73–S86 (1995).
   Google Scholar
• Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, Bockbrader HN. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res.40(2–3), 123–127 (2000).
   PubMed Web of Science ®Google Scholar
• Wymer JP, Simpson J, Sen D et al. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin. J. Pain25(5), 376–385 (2009).
   PubMed Web of Science ®Google Scholar
• Doty P, Rudd GD, Stoehr T et al. Lacosamide. Neurotherapeutics4, 145–148 (2007).
   PubMed Web of Science ®Google Scholar
• Armijo JA, Bravo J, Cuadrado A, Herranz JL. Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications. Ther. Drug Monit.21(2), 182–190 (1999).
   PubMedGoogle Scholar
• May TW, Rambeck B, Jürgens U. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther. Drug Monit.21(2), 175–181 (1999).
   PubMedGoogle Scholar
• Anderson GD, Yau MK, Gidal BE et al. Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin. Pharmacol. Ther.60(2), 145–156 (1996).
   PubMed Web of Science ®Google Scholar
• Ebert U, Thong NQ, Oertel R, Kirch W. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. Eur. J. Clin. Pharmacol.56(4), 299–304 (2000).
   PubMed Web of Science ®Google Scholar
• Kaufman KR, Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure7(2), 163–165 (1988).
   Google Scholar
• Reimers A, Skogvoll E, Sund JK, Spigset O. Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service. J. Clin. Psychopharmacol.25(4), 342–348 (2005).
   PubMed Web of Science ®Google Scholar
• Sidhu J, Job S, Singh S, Philipson R. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br. J. Clin. Pharmacol.61(2), 191–199 (2006).
   PubMed Web of Science ®Google Scholar
• Sabers A, Ohman I, Christensen J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology61(4), 570–571 (2003).
   PubMed Web of Science ®Google Scholar
• Christensen J, Petrenaite V, Atterman J et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia48(3), 484–489 (2007).
   PubMed Web of Science ®Google Scholar
• Ohman I, Luef G, Tomson T. Effects of pregnancy and contraception on lamotrigine disposition: new insights through analysis of lamotrigine metabolites. Seizure17(2), 199–202 (2008).
   PubMed Web of Science ®Google Scholar
• Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia46(9), 1414–1417 (2005).
   PubMed Web of Science ®Google Scholar
• Herzog AG, Blum AS, Farina EL et al. Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use. Neurology72(10), 911–914 (2009).
   PubMed Web of Science ®Google Scholar
• Reutens DC, Duncan JS, Patsalos PN. Disabling tremor after lamotrigine with sodium valproate. Lancet342, 185–186 (1993).
   PubMed Web of Science ®Google Scholar
• Besag FM, Berry DJ, Pool F et al. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia39(2), 183–187 (1998).
   PubMed Web of Science ®Google Scholar
• Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol. Ther.85, 77–85 (2000).
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Ghattaura S, Ratnaraj N, Sander JW. In situ metabolism of levetiracetam in blood of patients with epilepsy. Epilepsia47, 1818–1821 (2006).
   PubMedGoogle Scholar
• Sisodiya SM, Sander JW, Patsalos PN. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Res.48(3), 217–219 (2002).
   PubMed Web of Science ®Google Scholar
• Glauser TA, Pellock JM, Bebin EM et al. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia43(5), 518–524 (2002).
   PubMed Web of Science ®Google Scholar
• Volosov A, Bialer M, Xiaodong S, Perucca E, Sintov A, Yagen B. Simultaneous stereoselective high-performance liquid chromatographic determination of 10-hydroxycarbazepine and its metabolite carbamazepine-10,11-trans-dihydrodiol in human urine. J. Chromatogr. B Biomed. Sci. Appl.738(2), 419–425 (2000).
   PubMed Web of Science ®Google Scholar
• Tartara A, Galimberti CA, Manni R et al. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. Br. J. Clin. Pharmacol.36(4), 366–368 (1993).
   PubMed Web of Science ®Google Scholar
• May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin. Pharmacokinet.42(12), 1023–1042 (2003).
   PubMed Web of Science ®Google Scholar
• Hossain M, Sallas W, Gasparini M et al. Drug-drug interaction profile of oxcarbazepine in children and adults. Neurology52(Suppl. 2), A525 (1999).
   Google Scholar
• McKee PJ, Blacklaw J, Forrest G et al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br. J. Clin. Pharmacol.37(1), 27–32 (1994).
   PubMed Web of Science ®Google Scholar
• Sallas WM, Milosavljev S, D’souza J, Hossain M. Pharmacokinetic drug interactions in children taking oxcarbazepine. Clin. Pharmacol. Ther.74(2), 138–149 (2003).
   PubMed Web of Science ®Google Scholar
• Pisani F, Fazio A, Oteri G et al. Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy. Acta Neurol. Scand.90(2), 130–132 (1994).
   PubMedGoogle Scholar
• Fattore C, Cipolla G, Gatti G et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia40(6), 783–787 (1999).
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia45(Suppl. 6), 13–18 (2004).
   PubMed Web of Science ®Google Scholar
• Perucca E, Cloyd J, Critchley D et al. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia49(7), 1123–1141 (2008).
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Rosenfeld WE, Vazquez B et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia50(8), 1899–1909 (2009).
   PubMed Web of Science ®Google Scholar
• Glauser T, Kluger G, Sachdeo R et al. Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome. Neurology70(21), 1950–1958 (2008).
   PubMed Web of Science ®Google Scholar
• Levy RH, Lin HS, Blehaut HM, Tor JA. Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity. J. Clin. Pharmacol.23(11–12), 523–533 (1983).
   PubMed Web of Science ®Google Scholar
• Levy RH, Loiseau P, Guyot M, Blehaut HM, Tor J, Moreland TA. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin. Pharmacol. Ther.36(5), 661–669 (1984).
   PubMed Web of Science ®Google Scholar
• Tran A, Vauzelle-Kervroedan F, Rey E et al. Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children. Eur. J. Clin. Pharmacol.50(6), 497–500 (1996).
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ et al. Progress report on new antiepileptic drugs: a summary of the Eighth Eilat conference (Eilat VIII). Epilepsy Res.73, 1–52 (2007).
   PubMed Web of Science ®Google Scholar
• Chiron C. Stiripentol. Neurotherapeutics4(1), 123–125 (2007).
   PubMed Web of Science ®Google Scholar
• Chiron C, Marchand MC, Tran A et al. Stirpentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. Lancet356, 1638–1642 (2000).
   PubMed Web of Science ®Google Scholar
• Pollack MH, Roy-Byrne PP, Van Ameringen M et al. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J. Clin. Psychiatry66(11), 1401–1408 (2005).
   PubMed Web of Science ®Google Scholar
• Evans KC, Simon NM, Dougherty DD et al. A PET study of tiagabine treatment implicates ventral medial prefrontal cortex in generalized social anxiety disorder. Neuropsychopharmacology34(2), 390–398 (2009).
   PubMed Web of Science ®Google Scholar
• Wang X, Patsalos PN. The pharmacokinetic profile of tiagabine. Rev. Contemp. Pharmacother.12, 225–234 (2002).
   Google Scholar
• Adkins JC, Noble S. Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs55(3), 437–460 (1998).
   PubMed Web of Science ®Google Scholar
• Langtry HD, Gillis JC, Davis R. Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs54(5), 752–773 (1997).
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA, Yang LP. Topiramate: a review of its use in the treatment of epilepsy. Drugs67(15), 2231–2256 (2007).
   PubMed Web of Science ®Google Scholar
• Adín J, Gómez MC, Blanco Y, Herranz JL, Armijo JA. Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications. Ther. Drug Monit.26(3), 251–257 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenfeld WE, Liao S, Sica DA et al. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia38, 324–333 (1997).
   PubMed Web of Science ®Google Scholar
• Sachdeo RC, Sachdeo SK, Walker SA et al. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia37(8), 774–780 (1996).
   PubMed Web of Science ®Google Scholar
• Sachdeo RC, Sachdeo SK, Levy RH et al. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia43(7), 691–696 (2002); Erratum in: Epilepsia 43(10), 1273 (2002).
   PubMed Web of Science ®Google Scholar
• Contin M, Riva R, Albani F, Avoni P, Baruzzi A. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther. Drug Monit.24(3), 332–337 (2002).
   PubMedGoogle Scholar
• Liao S, Plamer M. Digoxin and topiramate drug interaction in male volunteers. Pharm. Res.10(Suppl.), 405 (1993) (Abstract).
   PubMedGoogle Scholar
• Bialer M, Doose DR, Murthy B et al. Pharmacokinetic interactions of topiramate. Clin. Pharmacokinet.43(12), 763–780 (2004).
   PubMed Web of Science ®Google Scholar
• Doose DR, Wang SS, Padmanabhan M, Schwabe S, Jacobs D, Bialer M. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia44(4), 540–549 (2003).
   PubMed Web of Science ®Google Scholar
• Conway M, Cubbidge RP, Hoskings SL. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia49, 108–116 (2008).
   PubMed Web of Science ®Google Scholar
• Walker MC, Patsalos PN. Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol. Ther.67(3), 351–384 (1995).
   PubMed Web of Science ®Google Scholar
• Gatti G, Bartoli A, Marchiselli R et al. Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability. Br. J. Clin. Pharmacol.36(6), 603–606 (1993).
   PubMedGoogle Scholar
• Kochak GM, Page JG, Buchanan RA, Peters R, Padgett CS. Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. J. Clin. Pharmacol.38(2), 166–171 (1998).
   PubMed Web of Science ®Google Scholar
• Ojemann LM, Shastri RA, Wilensky AJ et al. Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. Ther. Drug Monit.8(3), 293–296 (1986).
   PubMed Web of Science ®Google Scholar
• Fukuoka N, Uno J, Tsukamoto T et al. Dose adjustment of phenytoin for comedication in Japanese patients with epilepsy. Ther. Drug Monit.31(1), 57–62 (2009).
   PubMedGoogle Scholar
• Okumura K. Decrease in plasma zonisamide concentrations after coadministration of risperidone in a patient with schizophrenia receiving zonisamide therapy. Int. Clin. Psychopharmacol.14(1), 55 (1999).
   Google Scholar
• Johannessen Landmark C, Johannessen SI. Pharmacological management of epilepsy: recent advances and future prospects. Drugs68(14), 1925–1939 (2008).
   PubMed Web of Science ®Google Scholar
• Rolan P, Sargentini-Maier ML, Pigeolet E, et al. The pharmacokinetics, CNS pharmacodynamics and adverse effect profile of brivaracetam after multiple increasing oral doses in healthy men. Br. J. Clin. Pharmacol.66, 71–75 (2008).
   PubMed Web of Science ®Google Scholar
• Sargentini-Maier ML, Espie P, Coquette A, et al. Pharmacokinetics and metabolism of 14C-briavaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab. Dispos.36, 36–45 (2008).
   PubMed Web of Science ®Google Scholar
• Sargentini-Maier ML, Rolan P, Connell J, et al. The pharmacokinetics, CNS pharmacodynamics and adverse effect profile of brivaracetam after single increasing oral doses in healthy males. Br. J. Clin. Pharmacol.63, 680–688 (2007).
   PubMed Web of Science ®Google Scholar
• Otoul C, von Rosenstiel P, Stockis A. Evaluation of the pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with partial-onset seizures. Epilepsia48(Suppl. 6), 334 (2007) (Abstract).
   Google Scholar
• Mannens GS, Hendrickx J, Janssen CG, Chien S et al. The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1–2-chlorophenyl]-, 2-carbamate, [S]-) in humans. Drug Metab. Dispos.35(4), 554–565 (2007).
   PubMed Web of Science ®Google Scholar
• Yao C, Doose DR, Novak G, Bialer M. Pharmacokinetics of the new antiepileptic and CNS drug RWJ-333369 following single and multiple dosing to humans. Epilepsia47, 1822–1829 (2006).
   PubMed Web of Science ®Google Scholar
• Novak GP, Kelly M, Zannikos P et al. Carisbamate (RWJ-333369). Neurotherapeutics4, 106–109 (2007).
   PubMed Web of Science ®Google Scholar
• Levy R, Ragueneau-Majlessi I, Solanki B et al. Pharmacokinetics, safety, and tolerability of the new antiepileptic drug carisbamate (RWJ-333369) in the elderly. Epilepsy Res.79(1), 22–30 (2008).
   PubMedGoogle Scholar
• Chien S, Yao C, Mertens A et al. An interactions study between the new antiepileptic and CNS drug carisbamate (RWJ 333369) and lamotrigine and valproic acid. Epilepsia48(7), 1328–1338 (2007).
   PubMedGoogle Scholar
• Chien S, Bialer M, Solanki B. et al. Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults. Epilepsia47(11), 1830–1840 (2007).
   Google Scholar
• Parker RJ, Hartman NR, Roecklein BA et al. Stability and comparative metabolism of selected felbamate metabolites and postulated fluorofelbamate metabolites by postmitochondrial suspensions. Chem. Res. Toxicol.18, 1842–1848 (2005).
   PubMed Web of Science ®Google Scholar
• Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol. Rep.61, 197–216 (2009).
   PubMed Web of Science ®Google Scholar
• Monaghan EP, Navalta LA, Shum L et al. Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia38, 1026–1031 (1997).
   PubMed Web of Science ®Google Scholar
• Ferron GM, Patat A, Parks V et al. Lack of pharmacokinetic interactions between retigabine and phenobarbitone at steady-state in healthy subjects. Br. J. Clin. Pharmacol.56, 39–45 (2003).
   PubMed Web of Science ®Google Scholar
• Hermann R, Knebel NG, Niebch G et al. Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Eur. J. Clin. Pharmacol.58, 795–802 (2003).
   PubMed Web of Science ®Google Scholar
• Porter RJ, Nohria V, Rundfeldt C. Retigabine. Neurotherapeutics4, 149–154 (2007).
   PubMed Web of Science ®Google Scholar
• Langan YM, Lucas R, Jewell H, et al. Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia44, 46–53 (2003).
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res.51, 31–71 (2002).
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Berry DJ, Bourgeois BF et al. Antiepileptic drugs – best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia49(7), 1239–1276 (2008).
   PubMed Web of Science ®Google Scholar
• Aguglia U, Barboni G, Battino D, et al. Italian consensus conference on epilepsy and pregnancy, labor and puerperium. Epilepsia50(Suppl 1), 7–23 (2009)
   PubMed Web of Science ®Google Scholar
• Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia38(3), 317–323 (1997).
   PubMed Web of Science ®Google Scholar
• Eldon MA, Underwood BA, Randinitis EJ, Sedman AJ. Gabapentin does not interact with a contraceptive regimen of norethindrone acetate and ethinyl estradiol. Neurology50(4), 1146–1148 (1998).
   PubMed Web of Science ®Google Scholar
• Ragueneau-Majlessi I, Levy RH, Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia43(7), 697–702 (2002).
   PubMed Web of Science ®Google Scholar
• Bockbrader HN, Posvar EL, Hunt T, Randinitis EJ. Pregabalin does not alter the effectiveness of an oral contraceptive. Neurology (Suppl. 5), A314 (2004) (Abstract P04.097).
   Google Scholar
• Mengel HB, Houston A, Back DJ. An evaluation of the interaction between tiagabine and oral contraceptives in female volunteers. J. Pharm. Med.4, 141–150 (1994).
   Google Scholar
• Bartoli A, Gatti G, Cipolla G et al. A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. Epilepsia38(6), 702–707 (1997).
   PubMed Web of Science ®Google Scholar
• Griffith SG, Dai Y. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol–norethindrone oral contraceptive in healthy women. Clin. Ther.26(12), 2056–2065 (2004).
   PubMed Web of Science ®Google Scholar